Veradigm FCF Conversion
The FCF Conversion Rate (FCF/EBITDA) of Veradigm (MDRX) as of Jul 22, 2026 is -96.34 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -114.58 % — a change of -15.92% (higher).
Get this data via API
Financial Data API
FCF Conversion
-96.34 %
YoY
-15.92%
Last updated:
FCF Conversion Rate (FCF/EBITDA) of Veradigm is 2026 -96.34 % . FCF Conversion Rate (FCF/EBITDA) of Veradigm was 2025 -114.58 % . It decreases by -15.92% higher compared to the previous year.
Access this data via the Eulerpool API
Veradigm Stock analysis
What does Veradigm do? Allscripts Healthcare Solutions Inc is one of the leading companies in the digital healthcare sector in the USA. The company was founded in 1982 and has since become one of the most important providers of IT solutions in healthcare. Allscripts supports healthcare providers in improving patient care and efficiency through the development and provision of innovative software and IT solutions.
The business model of Allscripts is based on the development and sale of web-based software solutions for medical documentation and hospital management. These solutions are mainly distributed to hospitals and practices through subscriptions or licenses. Allscripts offers a variety of products that focus on various areas of medical care.
One of the main divisions of the company is the electronic health records system (EHR). This system allows for the electronic recording, storage, and management of medical data and information. This enables healthcare providers to quickly and easily access patient information and document important diagnoses and treatments. Another important division of Allscripts is the Revenue Cycle Management (RCM), which optimizes billing and payment processes in hospitals and practices. In addition, Allscripts also offers solutions for telemedicine, including patient portal applications, remote patient monitoring systems, and mobile apps for patients and providers.
Allscripts is based in Chicago and employs over 10,000 employees in various countries. The company also maintains partnerships with other companies in healthcare to facilitate and improve the complexity of digital transformation in the healthcare market. This includes companies like Microsoft, who work together with Allscripts on the development of artificial intelligence for healthcare applications.
Allscripts' portfolio of offerings is very broad and provides customers with a variety of software solutions for different areas of medical care. The products are particularly characterized by their user-friendly interfaces, flexibility, and scalability. This allows customers to customize the solutions to their specific needs and consider future requirements. However, some products have been criticized for their expandability, poor design, and slow loading times. Recently, Allscripts has made a number of investments in research and development to address these issues and optimize the applications.
In summary, Allscripts Healthcare Solutions Inc is considered one of the leading providers of software and IT solutions in healthcare in the USA. Thanks to a wide range of products and close collaboration with partners in healthcare, Allscripts is able to offer its customers innovative and scalable solutions that help them optimize their business processes and improve the quality of their medical care. Veradigm is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Veradigm stock
FCF Conversion Rate (FCF/EBITDA) of Veradigm is -96.34 % in 2026.
Access this data via the Eulerpool API
Cash Flow — Veradigm
Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A
All Key Metrics — Veradigm
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth